Results 141 to 150 of about 29,046 (192)

Influence of heparin-based anticoagulants on antibiotic therapy. [PDF]

Front Immunol
Cont D, Schildböck C, Kolm C, Kirschner AKT, Farnleitner AH, Hartmann J, Weber V, Harm S.   +7 more
europepmc   +1 more source

Perioperative Deep Vein Thrombosis in Elderly Patients with Lower Extremity Fracture: A Comprehensive Review of Anesthetic Management Strategies. [PDF]

Clin Appl Thromb Hemost
Jian Y, Liu Q, Wang F, Huang Z.
europepmc   +1 more source

Protein S Deficiency in Pregnancy, What Best Management at Satellite Hospital in Low-Middle Income Countries? [PDF]

Matern Fetal Med
Akyuni Q, Fachry M, Dwiningsih SR, Prasetyo B, Akbar M.   +4 more
europepmc   +1 more source

The rationale, design, and methods of a randomized, controlled trial to evaluate the efficacy and safety of an active strategy for the diagnosis and treatment of acute pulmonary embolism during exacerbations of chronic obstructive pulmonary disease [PDF]

, 2019
et al,, SLICE investigators,, Yusen, Roger   +2 more
core   +1 more source

Outcomes of patients with suspected heparin-induced thrombocytopenia in a contemporary multicenter cohort. [PDF]

Blood Adv
Nilius H, Sinitsa E, Studt JD, Tsakiris DA, Greinacher A, Mendez A, Schmidt A, Wuillemin WA, Gerber B, Vishnu P, Graf L, Kremer Hovinga JA, Bakchoul T, Nagler M.   +13 more
europepmc   +1 more source

Glycan-Induced Transchelation of Gadolinium from Magnetic Resonance Imaging Contrast Agent-Complexes. [PDF]

Anal Chem
Polewski L, Dymnikova D, Malicka W, Lettow M, von Helden G, Teutloff C, Ballauff M, Taupitz M, Bittl R, Pagel K.   +9 more
europepmc   +1 more source

[Superficial venous thrombosis, a necessary image]. [PDF]

Aten Primaria
Morena López D, Calvo Carrasco L, Morena López M.   +2 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Fondaparinux Sodium

Drugs of the Future, 2002
Fondaparinux (Org-31540 / SR-90107A) is a new drug chemically synthesized for treatment and prophylaxis of thromboembolic disease. Fondaparinux is a selective inhibitor of activated factor X. Its structure is the copy of the heparin pentasaccharide sequence, the shortest chain required for antithrombin inhibition of activated factor X without ...
Susan J, Keam, Karen L, Goa
  +8 more sources

Fondaparinux

Current Pharmaceutical Design, 2005
Fondaparinux is the first drug from the pentassaccharide factor X inhibitor class of anticoagulants to be approved for clinical use. It has been shown to be effective in the prevention of deep vein thrombosis in patients undergoing major orthopaedic surgery of the lower limbs. The drug is also being evaluated for use in the acute coronary syndromes and
Kiat T, Tan, Gregory Y H, Lip
openaire   +2 more sources